Photosensitising Diuretics and Skin Cancer Risk
Author Information
Author(s): A Ø Jensen, H F Thomsen, M C Engebjerg, A B Olesen, H T Sørensen, M R Karagas
Primary Institution: Aarhus University Hospital, Aarhus, Denmark
Hypothesis
Does the use of photosensitising diuretics increase the risk of developing skin cancers such as basal cell carcinoma, squamous cell carcinoma, and malignant melanoma?
Conclusion
The study found that the use of certain photosensitising diuretics is associated with an increased risk of squamous cell carcinoma and malignant melanoma.
Supporting Evidence
- An increased risk of squamous cell carcinoma was found among users of combined amiloride and hydrochlorothiazide therapy.
- Users of indapamide showed a significantly higher risk of malignant melanoma.
- Little association was found between diuretic use and basal cell carcinoma.
Takeaway
Some medicines that help with water retention can make your skin more sensitive to the sun, which might lead to skin cancer.
Methodology
A population-based case-control study was conducted in North Jutland County, Denmark, using cancer registry data and prescription records to analyze the association between diuretic use and skin cancer risk.
Potential Biases
Potential recall bias and differential registration of non-melanoma skin cancers could affect the results.
Limitations
The study relied on prescription data, which may not accurately reflect actual drug use, and there may be incomplete reporting of non-melanoma skin cancers.
Participant Demographics
The median age was 69 years for basal cell carcinoma cases, 77 years for squamous cell carcinoma cases, and 59 years for malignant melanoma cases.
Statistical Information
Confidence Interval
1.45–2.21 for SCC; 1.09–1.88 for MM; 1.34–8.10 for indapamide
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website